SGLT2 inhibitors, GLP-1 Receptor Agonists, and their combination in diabetic cardiomyopathy: A prospective cohort study

📖 Top 50% JournalMay 14, 2025Kardiologia polska

Effects of SGLT2 inhibitors, GLP-1 receptor agonists, and their combination on heart disease in diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

The incidence of all-cause death and hospitalization for heart failure was 23.7% in the SGLT2is combined with GLP-1RAs group.

SGLT2 inhibitors and GLP-1 receptor agonists may serve as independent protective factors against adverse cardiovascular events in symptomatic diabetic cardiomyopathy.
The SGLT2is + GLP-1RAs group showed the lowest incidence of the primary outcome compared to the SGLT2is group (32.5%), GLP-1RAs group (39.0%), and control group (53.6%).
In patients with heart failure of varying ejection fractions, SGLT2is or the combination with GLP-1RAs were associated with better outcomes.
GLP-1 receptor agonists alone did not show clinical benefits in the subgroup analysis.

AI simplified

BACKGROUND: The prevalence of diabetic cardiomyopathy (DiabCM) is increasing in parallel with diabetes mellitus, with no consensus on targeted treatment.

AIMS: This study aims to investigate the cardiovascular benefits of sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) alone and combination on symptomatic DiabCM participants.

MATERIAL AND METHODS: This was a single-center prospective cohort study focusing on patients with symptomatic DiabCM. The study comprised 587 participants: 154 in the SGLT2is group, 105 in the GLP-1RAs group, 93 in the SGLT2is combined with GLP-1RAs group (SGLT2is + GLP-1RAs), and 235 in the control group (without SGLT2is or GLP-1RAs). All participants were followed for 36 months. The primary outcome was a composite of all-cause death and hospitalization for heart failure.

RESULTS: The incidence of endpoint event was lowest in the SGLT2is + GLP-1RAs group (23.7%), followed by the SGLT2is group (32.5%), GLP-1RAs group (39.0%), and control group (53.6%). Multivariable Cox regression analysis showed that SGLT2is (P <0.001), GLP-1RAs (P = 0.02) or SGLT2is + GLP-1RAs prescription (P <0.001) were independent protective factors for the occurrence of primary outcome. In subgroup analysis, SGLT2is or SGLT2is + GLP-1RAs treatment remained the independent factors for freedom from primary outcome in both heart failure with reduced ejection fraction + heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction patients. However, GLP-1RAs alone did not exert clinical benefits in subgroup analysis.

CONCLUSIONS: SGLT2is and GLP-1RAs might reduce the incidence of all-cause mortality and heart failure hospitalization in patients with symptomatic DiabCM, and the combination of these two agents may further improve clinical outcomes.

Full Text

Full text is available at the source.

View full text ↗

Abstract

Full Text

Related papers